Femminella Grazia Daniela, Bencivenga Leonardo, Petraglia Laura, Visaggi Lucia, Gioia Lucia, Grieco Fabrizio Vincenzo, de Lucia Claudio, Komici Klara, Corbi Graziamaria, Edison Paul, Rengo Giuseppe, Ferrara Nicola
Neurology Imaging Unit, Imperial College London, London, UK.
Division of Geriatrics, Department of Translational Medical Sciences, Federico II University of Naples, Naples, Italy.
J Diabetes Res. 2017;2017:7420796. doi: 10.1155/2017/7420796. Epub 2017 Jun 1.
Diabetes mellitus (DM) and Alzheimer's disease (AD) are two highly prevalent conditions in the elderly population and major public health burden. In the past decades, a pathophysiological link between DM and AD has emerged and central nervous system insulin resistance might play a significant role as a common mechanism; however, other factors such as inflammation and oxidative stress seem to contribute to the shared pathophysiological link. Both preclinical and clinical studies have evaluated the possible neuroprotective mechanisms of different classes of antidiabetic medications in AD, with some promising results. Here, we review the evidence on the mechanisms of action of antidiabetic drugs and their potential use in AD.
糖尿病(DM)和阿尔茨海默病(AD)是老年人群中两种高度流行的疾病,也是主要的公共卫生负担。在过去几十年中,DM和AD之间出现了病理生理联系,中枢神经系统胰岛素抵抗可能作为一种共同机制发挥重要作用;然而,炎症和氧化应激等其他因素似乎也促成了这种共同的病理生理联系。临床前和临床研究都评估了不同类别的抗糖尿病药物在AD中的可能神经保护机制,并取得了一些有前景的结果。在此,我们综述了抗糖尿病药物作用机制及其在AD中潜在应用的证据。